Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.
Drug Resistance, Viral
/ genetics
Evolution, Molecular
Genotype
HIV Envelope Protein gp120
/ genetics
HIV Infections
/ drug therapy
HIV Integrase
/ genetics
HIV-1
/ genetics
Heterocyclic Compounds, 3-Ring
/ therapeutic use
Humans
Oxazines
Peptide Fragments
/ genetics
Piperazines
Pyridones
Viral Load
/ genetics
HIV-1
HIV-1 evolution
HIV-1 tropism
Integrase inhibitors
V3
Journal
Virus genes
ISSN: 1572-994X
Titre abrégé: Virus Genes
Pays: United States
ID NLM: 8803967
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
22
11
2018
accepted:
11
02
2019
pubmed:
24
2
2019
medline:
21
6
2019
entrez:
24
2
2019
Statut:
ppublish
Résumé
Integrase-strand-transfer inhibitors (INSTIs) are known to rapidly reduce HIV-1 plasma viral load, replication cycles, and new viral integrations, thus potentially limiting viral evolution. Here, we assessed the role of INSTIs on HIV-1 V3 evolution in a cohort of 89 HIV-1-infected individuals starting an INSTI- (N = 41, [dolutegravir: N = 1; elvitegravir: N = 3; raltegravir: N = 37]) or a non-INSTI-based (N = 48) combined antiretroviral therapy (cART), with two plasma RNA V3 genotypic tests available (one before [baseline] and one during cART). V3 sequences were analysed for genetic distance (Tajima-Nei model) and positive selection (dN/dS ratio). Individuals were mainly infected by B subtype (71.9%). Median (interquartile-range, IQR) plasma viral load and CD4 + T cell count at baseline were 4.8 (3.5-5.5) log
Identifiants
pubmed: 30796743
doi: 10.1007/s11262-019-01649-z
pii: 10.1007/s11262-019-01649-z
doi:
Substances chimiques
HIV Envelope Protein gp120
0
HIV envelope protein gp120 (305-321)
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Peptide Fragments
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
HIV Integrase
EC 2.7.7.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-297Subventions
Organisme : CHAIN
ID : 223131
Organisme : Italian Ministry of Health
ID : Project n. 2
Références
Mol Membr Biol. 1999 Jan-Mar;16(1):57-65
pubmed: 10332738
Lancet. 2001 Nov 24;358(9295):1760-5
pubmed: 11734232
J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):382-92
pubmed: 15764954
Trends Microbiol. 2005 Jun;13(6):269-77
pubmed: 15936659
Science. 2005 Nov 11;310(5750):1025-8
pubmed: 16284180
AIDS. 2007 Nov 12;21(17):2315-21
pubmed: 18090280
Clin Infect Dis. 2008 May 15;46(10):1617-23
pubmed: 18419499
J Antimicrob Chemother. 2009 Apr;63(4):795-804
pubmed: 19221102
Lancet. 2009 Sep 5;374(9692):796-806
pubmed: 19647866
New Microbiol. 2010 Jul;33(3):195-206
pubmed: 20954437
Antimicrob Agents Chemother. 2011 Feb;55(2):813-21
pubmed: 21115794
Lancet Infect Dis. 2011 May;11(5):394-407
pubmed: 21429803
AIDS. 2011 Nov 28;25(18):2269-78
pubmed: 21941167
Antivir Ther. 2011;16(7):1035-45
pubmed: 22024519
Lancet. 2012 Jun 30;379(9835):2429-2438
pubmed: 22748590
Lancet. 2012 Jun 30;379(9835):2439-2448
pubmed: 22748591
PLoS One. 2013;8(1):e53603
pubmed: 23341955
Theranostics. 2013;3(1):18-25
pubmed: 23382782
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
Lancet Infect Dis. 2013 Nov;13(11):927-35
pubmed: 24074642
N Engl J Med. 2013 Nov 7;369(19):1807-18
pubmed: 24195548
Lancet. 2014 Jun 28;383(9936):2222-31
pubmed: 24698485
J Antimicrob Chemother. 2014 Sep;69(9):2527-30
pubmed: 24840625
AIDS. 2015 Mar 27;29(6):659-65
pubmed: 25849829
Expert Rev Anti Infect Ther. 2015;13(10):1195-212
pubmed: 26293294
Medicine (Baltimore). 2016 Nov;95(44):e5222
pubmed: 27858869
Expert Opin Investig Drugs. 2017 Nov;26(11):1207-1213
pubmed: 28956664
Curr HIV Res. 2017;15(6):448-455
pubmed: 29210661
J Antimicrob Chemother. 2018 Apr 1;73(4):1045-1053
pubmed: 29244129
Mol Biol Evol. 1986 Sep;3(5):418-26
pubmed: 3444411
Mol Biol Evol. 1984 Apr;1(3):269-85
pubmed: 6599968
Ann Intern Med. 1993 May 1;118(9):681-8
pubmed: 8096374